Donna Weber

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone
    Richard B Wilder
    Department of Radiation Oncology, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 94:1532-7. 2002
  2. ncbi request reprint Newly diagnosed multiple myeloma
    Donna M Weber
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    Curr Treat Options Oncol 3:235-45. 2002
  3. ncbi request reprint Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
    Donna Weber
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:16-9. 2003
  4. ncbi request reprint Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    Donna M Weber
    Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 357:2133-42. 2007
  5. ncbi request reprint Thalidomide and its derivatives: new promise for multiple myeloma
    Donna Weber
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Control 10:375-83. 2003
  6. doi request reprint Symptom burden after autologous stem cell transplantation for multiple myeloma
    Erica Campagnaro
    Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:1617-24. 2008
  7. ncbi request reprint Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma
    Raymond Alexanian
    The University of Texas M D Anderson Cancer Center, Box 429, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Semin Hematol 40:3-7. 2003
  8. doi request reprint Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma
    Uday Popat
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:718-23. 2009
  9. ncbi request reprint Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes
    Anna V Christoforidou
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:543-9. 2007
  10. ncbi request reprint Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
    Athanasios Anagnostopoulos
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2607-12. 2004

Detail Information

Publications31

  1. ncbi request reprint Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone
    Richard B Wilder
    Department of Radiation Oncology, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 94:1532-7. 2002
    ..The authors analyzed multiple factors for myeloma-free survival (MFS) and cause-specific survival (CSS) in SPB patients treated with RT alone...
  2. ncbi request reprint Newly diagnosed multiple myeloma
    Donna M Weber
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    Curr Treat Options Oncol 3:235-45. 2002
    ..Its ease of administration along with stem cell preservation are likely to make this, followed by myeloablative therapy with stem cell support, the treatment of choice for untreated myeloma as confirmatory studies are completed...
  3. ncbi request reprint Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
    Donna Weber
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:16-9. 2003
    ..To evaluate the activity of thalidomide in patients with asymptomatic multiple myeloma and of thalidomide-dexamethasone in patients with previously untreated symptomatic myeloma...
  4. ncbi request reprint Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    Donna M Weber
    Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 357:2133-42. 2007
    ..Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma...
  5. ncbi request reprint Thalidomide and its derivatives: new promise for multiple myeloma
    Donna Weber
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Control 10:375-83. 2003
    ..In addition, preliminary results of phase I studies of the immunomodulatory derivatives (IMiDs) of thalidomide have recently been reported...
  6. doi request reprint Symptom burden after autologous stem cell transplantation for multiple myeloma
    Erica Campagnaro
    Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:1617-24. 2008
    ..Thorough assessment and understanding of symptoms and risk factors for symptom development after ASCT are logical first steps toward developing strategies aimed at reducing the symptom burden associated with this procedure...
  7. ncbi request reprint Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma
    Raymond Alexanian
    The University of Texas M D Anderson Cancer Center, Box 429, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Semin Hematol 40:3-7. 2003
    ..Our program of thalidomide/dexamethasone was a safe and effective combination for patients with resistant or relapsing disease, or as consolidation of partial remission after intensive therapy...
  8. doi request reprint Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma
    Uday Popat
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:718-23. 2009
    ..In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim. Remobilization with chemotherapy and filgrastim is usually successful in these patients...
  9. ncbi request reprint Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes
    Anna V Christoforidou
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:543-9. 2007
    ....
  10. ncbi request reprint Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
    Athanasios Anagnostopoulos
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2607-12. 2004
    ..In the current study, the authors compared the outcomes associated with high-dose melphalan (HDM) and a more intensive regimen of thiotepa, busulfan, and cyclophosphamide (TBC) in patients with multiple myeloma...
  11. ncbi request reprint Thalidomide and dexamethasone for resistant multiple myeloma
    Athanasios Anagnostopoulos
    University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 121:768-71. 2003
    ..This experience supports the use of thalidomide-dexamethasone in myeloma patients with resistant disease and justifies further trials in newly diagnosed patients...
  12. ncbi request reprint Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 47:1360-4. 2006
    ..We conclude that high tumor mass at diagnosis predicts a significantly shorter remission duration for myeloma patients undergoing autografting...
  13. ncbi request reprint High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma
    Michele L Donato
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Leuk Lymphoma 45:755-9. 2004
    ..With a median follow up of 12.3 months, 89% of patients are alive. The TMC regimen is well tolerated and produces high response rates. Further evaluation of TMC to fully assess response and survival is ongoing...
  14. ncbi request reprint 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials
    Sergio Giralt
    The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4006, USA
    Blood 102:2684-91. 2003
    ..With a minimum follow-up of 23 months, the median survival had not been reached and the median event-free survival was 22 months. 166Ho-DOTMP is a promising therapy for patients with multiple myeloma and merits further evaluation...
  15. ncbi request reprint Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
    Alok C Bharti
    Department of Bioimmunotherapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 103:3175-84. 2004
    ..Overall, our results indicate that fresh cells from MM patients express constitutively active NF-kappaB and STAT3, and suppression of these transcription factors inhibits the survival of the cells...
  16. doi request reprint International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
    S Giralt
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Leukemia 23:1904-12. 2009
    ..The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions...
  17. doi request reprint Advances in treatment for relapses and refractory multiple myeloma
    Tiffany Richards
    MD Anderson Cancer Center, Houston, TX, USA
    Med Oncol 27:S25-42. 2010
    ....
  18. doi request reprint Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma
    Gaurav C Parikh
    Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 15:812-6. 2009
    ..In this analysis, a melphalan (Mel) dose of 200 mg/m(2) was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM)...
  19. doi request reprint Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial
    Muzaffar H Qazilbash
    Department of Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1401-7. 2008
    ..Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a preparative regimen for MM...
  20. doi request reprint Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
    Michael Wang
    Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:4445-51. 2008
    ..Studies were registered at http://www.clinicaltrials.gov under NCT00056160 and NCT00424047...
  21. doi request reprint Novel agents for relapsed and/or refractory multiple myeloma
    Sheeba K Thomas
    Division of Cancer Medicine, Department of Lymphoma Myeloma, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Unit 429, Houston, TX 77030 4009, USA
    Cancer J 15:485-93. 2009
    ..In this review, we will discuss the use of these novel agents and their combinations in patients with relapsed and/or refractory multiple myeloma...
  22. ncbi request reprint Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant
    Muzaffar H Qazilbash
    Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:1066-72. 2007
    ..02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma...
  23. ncbi request reprint Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma
    Michael Wang
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 79:194-7. 2005
    ..Thalidomide-dexamethasone was useful for these patients with advanced disease because of the high response rate and acceptable survival, with a low frequency of serious complications...
  24. pmc Curability of multiple myeloma
    Raymond Alexanian
    University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Bone Marrow Res 2012:916479. 2012
    ..In addition to immunofixation, more sensitive techniques for the detection of residual disease should be applied more consistently in patients with apparent complete remission in order to identify those with potential cure...
  25. ncbi request reprint Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Donna Weber
    University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Semin Oncol 30:127-31. 2003
    ....
  26. ncbi request reprint Lenalidomide in multiple myeloma
    Sheeba K Thomas
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma and Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 20:717-35. 2007
    ..We describe the role of lenalidomide in patients with symptomatic multiple myeloma that is newly diagnosed, relapsed and/or refractory to other therapies, or concurrent with primary amyloidosis...
  27. pmc Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation
    Michele L Donato
    Department of Blood and Bone Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Blood 107:463-6. 2006
    ..High-dose melphalan followed by autologous transplantation appears effective for improving the symptoms and systemic manifestations of scleromyxedema...
  28. ncbi request reprint Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research Foundation
    Donna M Weber
    University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 17:765-7. 2003
    ..multiplemyeloma.org and will be published on a regular basis in ONCOLOGY...
  29. ncbi request reprint Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma
    Maha Ahmed
    Department of Hematopathology, M D Anderson Cancer Center, The University of Texas, Houston, TX 77030 4095, USA
    Eur J Haematol 71:174-8. 2003
    ..However, cytogenetic analysis in MM is frequently difficult because of poor yield of informative metaphases and the disease is frequently patchy, which complicates fluorescent in situ hybridization studies...
  30. ncbi request reprint 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia
    Donna M Weber
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Semin Oncol 30:243-7. 2003
    ..These observations support the potential role of 2-CdA regimens as the treatment of choice for previously untreated WM...
  31. ncbi request reprint Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Leuk Lymphoma 45:2057-61. 2004
    ..We conclude that rituximab is an effective treatment modality for patients with WM. Patients with both low levels of monoclonal protein and normal albumin are the best candidates for treatment with standard dose rituximab...